Good morning, everyone, and nice to see you again. We have finally returned from an extended break and, not surprisingly, are playing a bit of catch-up thanks to mounds of emails and other curious missives that arrived in our absence. To cope, yes, we are firing up the coffee kettle and brewing cups of needed stimulation. Our choice today is Jack Daniels (once again, folks, this is a real thing) and we invite you to join us. Remember, no prescription nor vaccine card is needed. Meanwhile, here are some tidbits to start you on your journey today. We hope all goes well and, as always, request that you keep us in mind when secret dossiers emerge and saucy tips can be passed on. …
A Biden administration plan to lower prescription-drug prices backs legislation from congressional Democrats, including a push to empower the federal government to negotiate for drug prices in Medicare and pass those lower costs to the private sector, The Wall Street Journal reports. The road map goes further, however, by outlining administrative actions by agencies and departments that could come in concert with possible legislative changes. Administrative measures include testing reimbursement for drugs in Medicare based on the clinical value they provide to patients and offering federal funding for research into new treatments.
Moderna (MRNA) is taking the first step in its novel respiratory vaccine program with the development of a single-dose vaccine that combines a booster against Covid-19 and a shot against the flu, MarketWatch writes. The company is also working on a next-generation vaccine against Covid-19 and an early-stage study is fully enrolled, according to information provided during a research and development briefing. In all, Moderna is addressing Covid-19 variants and has four development candidates.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
